Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene.

Blood
Denise E SabatinoKatherine A High

Abstract

Animal models have been critical to the development of novel therapeutics in hemophilia. A deficiency of current murine models of hemophilia B is that they are all due to gene deletions, a type of mutation that is relatively rare in the human hemophilia population. We generated mice with a range of mutations in the Factor IX (F.IX) gene; these more faithfully reflect the types of mutations that cause disease in the human population. Transgenic mice expressing either wild-type human F.IX (hF.IX), or F.IX variants with premature translation termination codons, or missense mutations, under the control of the murine transthyretin promoter, were generated and crossed with mice carrying a large deletion of the murine F.IX gene. Gene copy number, F.IX transcript levels in the liver, intrahepatocyte protein expression, and circulating levels of F.IX protein in the mice were determined and compared with data generated by transient transfection assays using the same F.IX variants. Mice were injected with a viral vector expressing hF.IX and displayed a range of immune responses to the transgene product, depending on the underlying mutation. These new mouse models faithfully mimic the mutations causing human disease, and will prove useful ...Continue Reading

References

Aug 1, 1991·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·P M GreenF Giannelli
Dec 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·J P EvansK A High
Feb 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·K M BrinkhousM S Read
Apr 1, 1967·Lancet·C Hougie, J J Twomey
Mar 10, 1995·The Journal of Biological Chemistry·S KurachiK Kurachi
Apr 2, 1996·Proceedings of the National Academy of Sciences of the United States of America·J WalterK A High
Jan 1, 1997·Nucleic Acids Research·F GiannelliG G Brownlee
Jan 1, 1997·Journal of Pediatric Hematology/oncology·I WarrierJ M Lusher
May 27, 1997·Proceedings of the National Academy of Sciences of the United States of America·R W HerzogK A High
Oct 23, 1997·Proceedings of the National Academy of Sciences of the United States of America·L WangI M Verma
Aug 17, 1999·The Journal of Clinical Investigation·E R Barton-DavisH L Sweeney
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·L WangI M Verma
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·P A FieldsK A High
Feb 7, 2001·Circulation Research·K A High
Sep 8, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·P A FieldsK A High
Jul 23, 2003·Journal of Thrombosis and Haemostasis : JTH·C Walsh
Oct 10, 2003·The New England Journal of Medicine·Michael WilschanskiEitan Kerem
Dec 20, 2003·Nature·Fred E Cohen, Jeffery W Kelly

❮ Previous
Next ❯

Citations

Apr 14, 2006·Human Genetics·Kenneth H Warrington, Roland W Herzog
Jul 16, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ou CaoRoland W Herzog
Apr 10, 2008·The Journal of Clinical Investigation·Majed N AljamaliKatherine A High
Jan 28, 2014·Journal of Translational Medicine·Geoffrey L RogersRoland W Herzog
Mar 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Eric DobrzynskiRoland W Herzog
Oct 10, 2013·EMBO Molecular Medicine·David M MarkusicRoland W Herzog
Sep 21, 2007·Proceedings of the National Academy of Sciences of the United States of America·Chunmei YangSteve S Sommer
Jun 11, 2005·Journal of Thrombosis and Haemostasis : JTH·C Hough, D Lillicrap
Apr 4, 2007·Journal of Thrombosis and Haemostasis : JTH·J J EmeisG J Johnson
May 19, 2006·Journal of Thrombosis and Haemostasis : JTH·M PinottiUNKNOWN International Factor VII Deficiency Study Group
Jan 16, 2008·Haemophilia : the Official Journal of the World Federation of Hemophilia·K ØvlisenM Tranholm
Nov 25, 2014·Haemophilia : the Official Journal of the World Federation of Hemophilia·B K SackD M Markusic
May 16, 2015·Cell Biology International·Hisataka KitanoHidai Chiaki
Oct 19, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Joerg SchuettrumpfValder R Arruda
Nov 20, 2004·Blood·Joerg SchuettrumpfValder R Arruda
Jan 24, 2020·Molecular Therapy. Methods & Clinical Development·Ashley T Martino, David M Markusic
Oct 10, 2021·Journal of Thrombosis and Haemostasis : JTH·Alessio BranchiniUNKNOWN GePKHIS Study Group of AICE

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.